HRT Financial’s Ginkgo Bioworks DNA Stock Holding History

HRT Financial’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-51,039	Closed	-$290K	–	2813
2025 Q1	$290K	Buy	+51,039	New	+$520K	﹤0.01%	1793
2024 Q3	–	Sell	-119,487	Closed	-$1.6M	–	2578
2024 Q2	$1.6M	Buy	119,487 +72,292	+153%	+$2.16M	0.01%	819
2024 Q1	$2.19M	Buy	47,195 +39,477	+511%	+$2.04M	0.01%	532
2023 Q4	$521K	Sell	7,718 -36,432	-83%	-$2.23M	﹤0.01%	1338
2023 Q3	$3.2M	Buy	+44,150	New	+$3.53M	0.03%	438
2023 Q2	–	Sell	-9,164	Closed	-$487K	–	2625
2023 Q1	$487K	Buy	+9,164	New	+$581K	0.01%	1410
2022 Q4	–	Sell	-11,368	Closed	-$1.42M	–	2597
2022 Q3	$1.42M	Buy	+11,368	New	+$1.35M	0.02%	738
2022 Q2	–	Sell	-190,064	Closed	-$30.6M	–	3083
2022 Q1	$30.6M	Buy	+190,064	New	+$37M	0.22%	53
2021 Q4	–	Sell	-5,831	Closed	-$2.7M	–	3353
2021 Q3	$2.7M	Buy	+5,831	New	+$2.84M	0.02%	556

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HRT Financial's DNA Position: Q2 2025 in Review

HRT Financial sold out of Ginkgo Bioworks (DNA) in Q2 2025, closing a stake of 51,039 shares — an estimated $290K sold.

HRT Financial first reported a position in DNA in Q3 2021 and held it in 9 quarters. The position peaked at $30.6M in Q1 2022. 166 funds tracked by Wall St. Rank hold DNA as of Q2 2025.

HRT Financial reported no remaining Ginkgo Bioworks position as of Q2 2025 after selling out during the quarter.
HRT Financial sold 51,039 Ginkgo Bioworks shares in Q2 2025, an estimated $290K.
HRT Financial first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 9 quarters.
HRT Financial's Ginkgo Bioworks position peaked at $30.6M in Q1 2022.
166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.